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BeckwitheWiedemann syndrome (BWS) predisposes to embryonic tumors. The concomitant presence of
pathologically different tumors requires patient-speciﬁc surgical care. We report a case of simultaneous
occurrence of a hepatoblastoma (HB) and an infantile hepatic hemangioma (IHH). A 4-month-old girl
with BWS presented with two liver masses (one in segment VI/V and the other in segment VII). Biopsy of
the larger lesion conﬁrmed the diagnosis of HB. Standard chemotherapy was started and a right hepa-
tectomy was planned. The two masses reacted differently to chemotherapy, with a marked decrease in
the size of the larger tumor, and no change in the size of the smaller one. Thus, after four chemotherapy
cycles, enucleation of the smaller of the two masses was performed and intraoperative examination of
the specimen revealed the presence of an IHH. Segmentectomy of the second, larger tumor was then
performed, instead of the originally planned right hepatectomy. The presence of both HB and IHH in
children with BWS is rare. Early recognition of the two different tumors allows for patient-speciﬁc
surgical care, with resection of less liver tissue. This is important in children with BWS given the
persistent lifelong risk for additional liver tumors requiring liver resections.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. BeckwitheWiedemann syndrome (BWS) is a well-known over-
growth syndrome. It predisposes to embryonic tumors such as
Wilms’ renal tumor, neuroblastoma, aswell as hepatoblastoma (HB).
Benign tumors, such as hepatic hemangioma, adrenal adenoma and
teratoma are rarer [1,2]. We report a case of a 6-month old girl with
BWS, who presented both a unifocal HB and an infantile hepatic
hemangioma (IHH). In such a case, a patient-speciﬁc treatment plan
is suggested.1. Case report
We report a case of a 34-week old premature infant who pre-
sentedwith BWS (parental paternal unidisomy 11p) associatedwith
macroglossia, enlarged liver and kidneys, and an umbilical hernia.
At four months of age, a routine screening ultrasound revealed two
liver masses. AnMRI was performed: the larger mass was located in
segments IV and V andmeasured 5 cm in diameter; the secondmassvice Chirurgie Pédiatrique,
s du Foie de l’Enfant, Hôpital
illy-Donzé 6, 1211 Genève 14,
46 66.
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-NC-ND license. was in segment VII and measured 1.5 cm (Fig. 1A and B). A biopsy of
the larger lesion revealed the presence of a fetal type HB. Staging
workup showed no evidence of metastases. Because the presence of
these two tumors, the extensionwas classiﬁed as a bifocal PRETEXT
III, and the plan was to perform right hepatectomy (right tri-
segmentectomy) following chemotherapy. Chemotherapy with
Cystatin was started according to the European SIOPEL standard-
risk protocol. This resulted in a signiﬁcant regression of the tumor in
segments IV and V. The alpha-fetoprotein, initially measured at
238,963 mg/l, decreased to 725 mg/l after four cycles of chemo-
therapy. A post-chemotherapy CT scan demonstrated a clear
regression in the size of the lesion in segment IV and V, but no
change in the size of the tumor in segment VII (Fig. 1C and D). Of
note, the smaller tumor showed increased uptake of contrast thus
raising the suspicion for a vascular lesion.
Because of these unusual ﬁndings, the surgical strategy was
changed: instead of performing an immediate right liver hepatec-
tomy, as originally planned for this HB PRETEXT III, an in-toto
enucleation of the lesion in segment VII was performed ﬁrst. The
intra-operative frozen section revealed the diagnosis of a benign
IHH. Thus it was decided not to perform a right hepatectomy, but
only a segmentectomy of the segments IV anterior and V. Histo-
logical examination showed no residual tumor with negative
margins. The ﬁnal histological diagnosis was a mixed epithelial-
Fig. 1. MRI (A and B) and CT (C and D) images of the liver. Infantile hemangioma (A)
and hepatoblastoma (B) at the time of diagnosis; Infantile hepatic hemangioma (C) and
hepatoblastoma (D) after chemotherapy. Note the unchanged, vascular appearance of
the infantile hemangioma; the hepatoblastoma clearly responded to chemotherapy.
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nosis on the biopsy. There were no complications during the
postoperative period. The last two cycles of chemotherapy were
successfully administered. Four years following surgery the girl
remains healthy with no signs of recurrence.Table 1
Comparison of characteristics of hepatoblastoma and infantile hepatic hemangioma.
Hepatoblastoma Infantile hepatic
hemangioma
Imaging Abdominal
ultrasound:
hyper-echogenic
and heterogeneous
mass.
CT scan with
contrast: “patchy”
areas.
Abdominal ultrasound:
heterogeneous lesion with
hypo-and iso-echogenic areas
and increased blood ﬂow. If IHH
is large, a widening of the
proximal aorta and a low
resistance in the hepatic artery
are visible on Doppler.
CT scan: vascular lesion.
Necessity of biopsy Diagnosis is based
on histology and
must be made by
a biopsy.
Biopsy of the lesion is neither
necessary nor appropriate for
the diagnosis (risk of bleeding).
Response to medical
treatment
Chemotherapy:
good response with
often clear
regression of the
tumor.
Chemotherapy: no response.
Beta-blockers, steroids,
interferon alpha: regression.
Surgical treatment Partial or total
hepatectomy.
Only if the tumor is
symptomatic and medical or
interventional radiological
treatment not effective.2. Discussion
BWS, the most well-known overgrowth syndrome [1], affects 1/
13,700 children [1,3]. Its primary diagnostic criteria include the
presence of omphalocele, macroglossia, and macrosomia [2].
Secondary diagnostic criteria are: hypoglycemia at birth, i.e.,
a hyperplasia of the islets of Langerhans [2]; nevus ﬂammeus [2];
infraorbital folds and abnormal morphology of the ears; hemi-
hyperplasia [2,4e6]; and associated embryonic tumors (7.5% of
cases) [1,2]. Thus, regular monitoring with abdominal ultrasounds,
to detect potential cancers is warranted [5,7]. The genetic basis of
the syndrome is complex; 85% of cases are sporadic. In the
remaining 15%, there is an autosomal dominant transmission [8].
BWS is caused by the alteration of growth regulatory genes on
chromosome 11p15. This region, subject to genomic imprinting,
contains two clusters of genes that are methylated and expressed
according to their parental origin. These regions are called differ-
ently methylated regions (DMR) 1 and 2 [9], and their disruption
can cause an increase in the expression of insulin-like growth factor
2 or decreased expression of cyclin-dependent kinase inhibitor 1C
(CDKN1C), a tumor suppressor gene; both events cause. Paternal
parental unidisomy correlates with the most severe phenotype and
increased risk of tumors [1,9]. The infant presented in our report
shows this genotype and was therefore at a high risk for early
development of tumors.
HB is the most common malignant liver tumor in children and
primarily affects two to three year-old children [10]. Imaging features
are summarized in Table 1. As in our patient, HBmost often affects the
right lobe of the liver [11]. The diagnosis is solely based on histology
and must be made by biopsy [7]. Like other pediatric tumors, the
cause of the HB is not fully understood. Yet, the similarities between
the development of fetal liver cells and fetal epithelial-type HB are
striking. A developmental disorder of the liver during embryogenesis
may result in aberrant proliferation of undifferentiated cells from
precursor liver cells. Data suggest that abnormal transduction of theWnt/b-catenin gene and its molecular targets play a role in the HB
tumor genesis [12]. Risk factors for HB development include BWS,
familial adenomatous polyposis syndrome, Li Fraumeni, trisomy 21 or
18 and Fanconi anemia predispose to HB development [2]. The loss of
the heterogeneity in chromosome 11p in BWS associated with the
production of insulin-like growth factor 2 may be a mechanism for
the development of HB [13].
The complete removal of the tumor is a crucial step in HB
treatment and is usually performed after preoperative chemo-
therapy, as suggested by SIOPEL, to reduce the tumor size to opti-
mize partial hepatectomy [14e16]. Non-anatomic, or wedge
resections are not recommended [16]. In the case of pure fetal HB
a primary resection may be attempted to avoid toxic chemotherapy
[17]. To date this approach has not been accepted by SIOPEL and is
rarely done in Europe. Nevertheless it is slowly gaining more
acceptance. Of note, in our case ﬁnal HB histology of the excised
tumor showed a mixed epithelial-mesenchymal type, this in
contrast to the diagnosis of pure fetal type HB on the initial biopsy;
the SIOPEL strategy ﬁnally proved to be adequate.
IHH of the liver is a benign vascular tumor accounting for 60% of
liver tumors in children [10]. In the European terminology IHH is
also called infantile hepatic hemangioendothelioma [18], yet the
modern term IHH is gaining more and more use [19]. This tumor is
most often found in children less than six months old [20]. IHHs can
be focal, multifocal or diffuse, but are most commonly multiple and
bilobar. Characteristic images are described in Table 1. Biopsy of the
lesion is neither necessary, nor appropriate to obtain the diagnosis,
because of the high risk of bleeding during such a procedure [10].
BWS predisposes to hepatic hemangioma: a study showed that
IHHs associated with BWS do not express the gene p57, a tumor
suppressor gene. However, endothelial cells of infantile heman-
gioma located on the skin, mammary glands, and salivary glands
show normal expression of p57. This study suggests that IHH in
BWS results from a cycle deregulation and increased cell replication
due to the loss of p57 [21]. Another study suggests that IHH is
associated with the production of insulin-like growth factor 2,
which results in molecular changes and subsequent tumor devel-
opment [13]. Spontaneous regression of IHH is often observed [18].
If the IHH is asymptomatic, expectant management can safely be
adopted. In symptomatic cases (i.e., KasabacheMerritt syndrome)
medical, radiologic, or surgical treatment is indicated [22].
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the genetic changes related to BWS may cause an increase in the
expression of insulin-like growth factor 2, which is strongly linked
to the development of these tumors [13]. In reviewing the literature,
we found only two other reported cases. The ﬁrst case is one of
a four-month-old with BWS and increased AFP who was found to
have two livermasses in adjacent segments. Biopsy conﬁrmedHB in
one mass; the other tumor was found to be a hemangioma.
Management consisted of neoadjuvant chemotherapy followed by
surgical resection of the HB only, leaving the hemangioma in situ.
The hemangioma of the patient regressed with time and there was
no HB recurrence [4]. A second case of an HB in a patient with BWS
was reported, following total resection of a liver mass. The ﬁnal
pathology revealed the presence of a hepatic cavernous heman-
gioma [23]. These examples and our case suggest that IHHmight be
under-diagnosed and may be confused with HB, as they can occur
simultaneously. We propose that the early distinction between the
two is crucial because it results in more appropriate care. Table 1
summarizes the main characteristics of HB and IHH.
Upon the discovery of one or more liver masses, especially in
a childwith BWS, onemust be particularly careful when interpreting
the ultrasound or MRI/CT-scan. We have found that misdiagnosis of
the different tumors can have signiﬁcant consequences: in our case,
if the two lesions had been located in both the left and right liver
lobes, and presumed to be both HB, we would have considered
a total hepatectomywith liver transplantation. As outlined in Table 1,
HB and IHH appear differently on imaging, yet, these characteristics
are not always very distinct and differentiation between the two
entities can be difﬁcult. The diagnosis of HB is always based on
histology and must be made by a biopsy of the primary tumor. IHH
biopsy is usually not necessary for diagnosis. Children with BWS
presenting with suspicious hepatic lesions should undergo biopsy of
all lesions as previously proposed by Madan and Lewis [20]. It is
crucial to eliminate the diagnosis of HB, because of the increased
incidence in these children. In our case, the diagnosis of concomitant
HB and IHH was missed on the ﬁrst MRI-scan, and only the IHH’s
non-response to chemotherapy and its unusual appearance on the
follow-up CT-scan raised the suspicion of the presence of two tumor
types. Once the distinction between the two tumors is made, the
treatment must be tailored to the patient. HB should be treated with
chemotherapy to reduce its PRETEXT to allow amore limited hepatic
resection. The IHH, a vascular tumor, could even be left in place as it
tends to regress with time.
3. Conclusion
In patients with BWS, the presence of multifocal liver tumors
must raise the suspicion of multiple pathologic entities. The diag-
nosis of each liver mass must be obtained. If imaging results are
equivocal, we suggest biopsy of each mass. Recognition of benign
tumors is crucial in children suffering from BWS, because it allows
a more conservative and patient-speciﬁc treatment approach that
preserves liver tissue. Preservation of liver capital is necessary given
the lifelong risk of additional liver tumors requiring resection.
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